{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:09:50Z","timestamp":1790662190670,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Department of Health & Human Services | U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["HHSF223201810172C"],"award-info":[{"award-number":["HHSF223201810172C"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000104","name":"National Aeronautics and Space Administration","doi-asserted-by":"publisher","award":["NNX16AO69A"],"award-info":[{"award-number":["NNX16AO69A"]}],"id":[{"id":"10.13039\/100000104","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19 AI135995"],"award-info":[{"award-number":["U19 AI135995"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI42790"],"award-info":[{"award-number":["U19AI42790"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI146785"],"award-info":[{"award-number":["R01AI146785"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U19AI135995"],"award-info":[{"award-number":["U19AI135995"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U19AI42790"],"award-info":[{"award-number":["U19AI42790"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["1U01CA260476"],"award-info":[{"award-number":["1U01CA260476"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["CIVIC75N93019C00052"],"award-info":[{"award-number":["CIVIC75N93019C00052"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Antibodies serve as biomarkers of infection, but if sustained can confer long-term immunity. Yet, for most clinically approved vaccines, binding antibody titers only serve as a surrogate of protection. Instead, the ability of vaccine induced antibodies to neutralize or mediate Fc-effector functions is mechanistically linked to protection. While evidence has begun to point to persisting antibody responses among SARS-CoV-2 infected individuals, cases of re-infection have begun to emerge, calling the protective nature of humoral immunity against this highly infectious pathogen into question. Using a community-based surveillance study, we aimed to define the relationship between titers and functional antibody activity to SARS-CoV-2 over time. Here we report significant heterogeneity, but limited decay, across antibody titers amongst 120 identified seroconverters, most of whom had asymptomatic infection. Notably, neutralization, Fc-function, and SARS-CoV-2 specific T cell responses were only observed in subjects that elicited RBD-specific antibody titers above a threshold. The findings point to a switch-like relationship between observed antibody titer and function, where a distinct threshold of activity\u2014defined by the level of antibodies\u2014is required to elicit vigorous humoral and cellular response. This response activity level may be essential for durable protection, potentially explaining why re-infections occur with SARS-CoV-2 and other common coronaviruses.<\/jats:p>","DOI":"10.1038\/s41467-021-21336-8","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T14:31:41Z","timestamp":1613572301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Discrete SARS-CoV-2 antibody titers track with functional humoral stability"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3844-3056","authenticated-orcid":false,"given":"Yannic C.","family":"Bartsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2307-3379","authenticated-orcid":false,"given":"Stephanie","family":"Fischinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameed M.","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyou","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makda","family":"Gebre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7489-0232","authenticated-orcid":false,"given":"Caroline","family":"Atyeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1712-8310","authenticated-orcid":false,"given":"Alex Lee","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0846-4611","authenticated-orcid":false,"given":"Jaewon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1282-8211","authenticated-orcid":false,"given":"John S.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8288-787X","authenticated-orcid":false,"given":"Matthew","family":"Slein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Gluck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Beger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6530-211X","authenticated-orcid":false,"given":"Yiyuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0656-3261","authenticated-orcid":false,"given":"Justin","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Mormann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael de St","family":"Aubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3100-9660","authenticated-orcid":false,"given":"Mohammad A.","family":"Hasdianda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprasad","family":"Jambaulikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3454-1310","authenticated-orcid":false,"given":"Edward W.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardis C.","family":"Sabeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5127-4659","authenticated-orcid":false,"given":"Dan H.","family":"Barouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris D.","family":"Julg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elon R.","family":"Musk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil S.","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0050-989X","authenticated-orcid":false,"given":"Douglas A.","family":"Lauffenburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7044-5257","authenticated-orcid":false,"given":"Eric J.","family":"Nilles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-9215","authenticated-orcid":false,"given":"Galit","family":"Alter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"21336_CR1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","volume":"584","author":"DF Robbiani","year":"2020","unstructured":"Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584, 437\u2013442 (2020).","journal-title":"Nature"},{"key":"21336_CR2","unstructured":"Iyer, A. S. et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. eabe0367 (2020)."},{"key":"21336_CR3","doi-asserted-by":"crossref","unstructured":"To, K. K. et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin. Infect. Dis. ciaa1275 (2020).","DOI":"10.1093\/cid\/ciaa1275"},{"key":"21336_CR4","doi-asserted-by":"crossref","unstructured":"Tillett, R. et al. Genomic evidence for a case of reinfection with SARS-CoV-2 SSRN (2020).","DOI":"10.2139\/ssrn.3680955"},{"key":"21336_CR5","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","volume":"26","author":"QX Long","year":"2020","unstructured":"Long, Q. X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 26, 845\u2013848 (2020).","journal-title":"Nat. Med."},{"key":"21336_CR6","doi-asserted-by":"publisher","first-page":"362","DOI":"10.7326\/M20-3012","volume":"173","author":"DP Oran","year":"2020","unstructured":"Oran, D. P. & Topol, E. J. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. Ann. Intern. Med. 173, 362\u2013367 (2020).","journal-title":"Ann. Intern. Med."},{"key":"21336_CR7","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","volume":"26","author":"QX Long","year":"2020","unstructured":"Long, Q. X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 26, 1200\u20131204 (2020).","journal-title":"Nat. Med."},{"key":"21336_CR8","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.molmed.2016.09.002","volume":"22","author":"BM Gunn","year":"2016","unstructured":"Gunn, B. M. & Alter, G. Modulating antibody functionality in infectious disease and vaccination. Trends Mol. Med. 22, 969\u2013982 (2016).","journal-title":"Trends Mol. Med."},{"key":"21336_CR9","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1126\/science.abc6284","volume":"369","author":"J Yu","year":"2020","unstructured":"Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369, 806\u2013811 (2020).","journal-title":"Science"},{"key":"21336_CR10","doi-asserted-by":"crossref","unstructured":"Mercado, N. B. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature 586, 583\u2013588 (2020).","DOI":"10.1038\/s41586-020-2607-z"},{"key":"21336_CR11","doi-asserted-by":"crossref","unstructured":"Nilles, E. J. et al. Evaluation of two commercial and two non-commercial immunoassays for the detection of prior infection to SARS-CoV-2. Preprint at https:\/\/www.medrxiv.org\/content\/10.1101\/2020.06.24.20139006v2 (2020).","DOI":"10.1101\/2020.06.24.20139006"},{"key":"21336_CR12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/0966-842X(96)10059-7","volume":"4","author":"MK Slifka","year":"1996","unstructured":"Slifka, M. K. & Ahmed, R. Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity. Trends Microbiol. 4, 394\u2013400 (1996).","journal-title":"Trends Microbiol."},{"key":"21336_CR13","unstructured":"Gudbjartsson, D. F. et al. Humoral immune response to SARS-CoV-2 in Iceland. N. Engl. J. Med. 383, 1724\u20131734 (2020)."},{"key":"21336_CR14","doi-asserted-by":"crossref","unstructured":"Ibarrondo, F. J. et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N. Engl. J. Med. 383, 1085\u20131087 (2020).","DOI":"10.1056\/NEJMc2025179"},{"key":"21336_CR15","doi-asserted-by":"publisher","first-page":"e00622","DOI":"10.1128\/mSphere.00622-20","volume":"5","author":"C Loos","year":"2020","unstructured":"Loos, C. et al. Evolution of early SARS-CoV-2 and cross-coronavirus immunity. mSphere 5, e00622 (2020).","journal-title":"mSphere"},{"key":"21336_CR16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.immuni.2020.07.005","volume":"53","author":"A Sariol","year":"2020","unstructured":"Sariol, A. & Perlman, S. Lessons for COVID-19 immunity from other coronavirus infections. Immunity 53, 248\u2013263 (2020).","journal-title":"Immunity"},{"key":"21336_CR17","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41591-020-0913-5","volume":"26","author":"F Amanat","year":"2020","unstructured":"Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 26, 1033\u20131036 (2020).","journal-title":"Nat. Med."},{"key":"21336_CR18","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489\u20131501.e1415 (2020).","journal-title":"Cell"},{"key":"21336_CR19","doi-asserted-by":"crossref","unstructured":"Braun, J. et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature 587, 270\u2013274 (2020).","DOI":"10.1038\/s41586-020-2598-9"},{"key":"21336_CR20","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1126\/science.abc4776","volume":"369","author":"A Chandrashekar","year":"2020","unstructured":"Chandrashekar, A. et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science 369, 812\u2013817 (2020).","journal-title":"Science"},{"key":"21336_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1086\/589862","volume":"47","author":"SA Plotkin","year":"2008","unstructured":"Plotkin, S. A. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47, 401\u2013409 (2008).","journal-title":"Clin. Infect. Dis."},{"key":"21336_CR22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nri.2017.106","volume":"18","author":"LL Lu","year":"2018","unstructured":"Lu, L. L., Suscovich, T. J., Fortune, S. M. & Alter, G. Beyond binding: antibody effector functions in infectious diseases. Nat. Rev. Immunol. 18, 46\u201361 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"21336_CR23","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","volume":"17","author":"SA Plotkin","year":"2010","unstructured":"Plotkin, S. A. Correlates of protection induced by vaccination. Clin. Vaccin. Immunol. 17, 1055\u20131065 (2010).","journal-title":"Clin. Vaccin. Immunol."},{"key":"21336_CR24","doi-asserted-by":"publisher","first-page":"eabb4757","DOI":"10.1126\/scitranslmed.abb4757","volume":"12","author":"TJ Suscovich","year":"2020","unstructured":"Suscovich, T. J. et al. Mapping functional humoral correlates of protection against malaria challenge following RTS,S\/AS01 vaccination. Sci. Transl. Med. 12, eabb4757 (2020).","journal-title":"Sci. Transl. Med."},{"key":"21336_CR25","doi-asserted-by":"crossref","unstructured":"Yuan, M. et al. Structural basis of a shared antibody response to SARS-CoV-2. Science 359, 1119\u20131123 (2020).","DOI":"10.1126\/science.abd2321"},{"key":"21336_CR26","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1080\/22221751.2020.1791738","volume":"9","author":"L Liu","year":"2020","unstructured":"Liu, L. et al. High neutralizing antibody titer in intensive care unit patients with COVID-19. Emerg. Microbes Infect. 9, 1664\u20131670 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"21336_CR27","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","volume":"5","author":"G Vidarsson","year":"2014","unstructured":"Vidarsson, G., Dekkers, G. & Rispens, T. IgG subclasses and allotypes: from structure to effector functions. Front. Immunol. 5, 520 (2014).","journal-title":"Front. Immunol."},{"key":"21336_CR28","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S1473-3099(10)70049-9","volume":"10","author":"SL Klein","year":"2010","unstructured":"Klein, S. L., Jedlicka, A. & Pekosz, A. The Xs and Y of immune responses to viral vaccines. Lancet Infect. Dis. 10, 338\u2013349 (2010).","journal-title":"Lancet Infect. Dis."},{"key":"21336_CR29","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1016\/j.vaccine.2017.07.062","volume":"36","author":"GA Poland","year":"2018","unstructured":"Poland, G. A., Ovsyannikova, I. G. & Kennedy, R. B. Personalized vaccinology: a review. Vaccine 36, 5350\u20135357 (2018).","journal-title":"Vaccine"},{"key":"21336_CR30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41577-020-0389-z","volume":"20","author":"A Sette","year":"2020","unstructured":"Sette, A. & Crotty, S. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. Nat. Rev. Immunol. 20, 457\u2013458 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"21336_CR31","unstructured":"Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N. Engl. J. Med. 383, 1920\u20131931 (2020)."},{"key":"21336_CR32","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet 396, 467\u2013478 (2020).","journal-title":"Lancet"},{"key":"21336_CR33","doi-asserted-by":"crossref","unstructured":"Keech, C. et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N. Engl. J. Med. 383, 2320\u20132332 (2020).","DOI":"10.1056\/NEJMoa2026920"},{"key":"21336_CR34","doi-asserted-by":"crossref","unstructured":"Mulligan, M. J. et al. Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586, 589\u2013593 (2020).","DOI":"10.1038\/s41586-020-2639-4"},{"key":"21336_CR35","doi-asserted-by":"crossref","unstructured":"Roy, V. et al. SARS-CoV-2-specific ELISA development. J. Immunol. Methods 484, 112832 (2020).","DOI":"10.1016\/j.jim.2020.112832"},{"key":"21336_CR36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jim.2018.01.013","volume":"455","author":"EP Brown","year":"2018","unstructured":"Brown, E. P. et al. Optimization and qualification of an Fc Array assay for assessments of antibodies against HIV-1\/SIV. J. Immunol. Methods 455, 24\u201333 (2018).","journal-title":"J. Immunol. Methods"},{"key":"21336_CR37","doi-asserted-by":"publisher","first-page":"112630","DOI":"10.1016\/j.jim.2019.07.002","volume":"473","author":"S Fischinger","year":"2019","unstructured":"Fischinger, S. et al. A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation. J. Immunol. Methods 473, 112630 (2019).","journal-title":"J. Immunol. Methods"},{"key":"21336_CR38","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jim.2019.05.006","volume":"471","author":"CB Karsten","year":"2019","unstructured":"Karsten, C. B. et al. A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis. J. Immunol. Methods 471, 46\u201356 (2019).","journal-title":"J. Immunol. Methods"},{"key":"21336_CR39","doi-asserted-by":"crossref","unstructured":"Atyeo, C. et al. Distinct early serological signatures track with SARS-CoV-2 survival. Immunity 53, 524\u2013532.e4 (2020).","DOI":"10.1016\/j.immuni.2020.07.020"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21336-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21336-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21336-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T10:47:23Z","timestamp":1669978043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21336-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["21336"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-21336-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"10 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.A. is a founder of Seromyx Systems Inc. P.C. S. is a co-founder of, a shareholder in, and advisor to Sherlock Biosciences Inc, as well as a Board member of and shareholder in Danaher Corporation. M. J. Gluck, S.B., Y.H., J.R., E.P., B.M., A.S.M., and E.R.M. are employees of Space Exploration Technologies Corp. All other authors have declared that no conflict of interest exists.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1018"}}